Please assess the completion status of the following clinical trial:

Trial Title: Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged over 18 years old;~* Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the colon, rectum or cancer of the pancreas;~* Both pancreatic and colorectal cancer patients: Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml);~* Patient suffering from recurrences and metastasis of colorectal cancer: Rising circulating plasma CEA~* Patients should be capable and willing to give informed consent before study specific procedures.~Exclusion Criteria:~* Anticancer therapy (e.g. chemotherapy, radiotherapy (except for routine pre-operative radiotherapy for colorectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion;~* History of a clinically significant allergy;~* Circulating plasma concentration CEA ≥ 300 ng / ml;~* Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;~* Patients pregnant or breastfeeding (pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate), lack of effective contraception in male or female patients with reproductive potential;~* Laboratory abnormalities defined as:~Colorectal cancer patients only:~* Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;~* Total bilirubin above 2 times the Upper Limit Normal (ULN) or; Both pancreatic and colorectal cancer patients:~* Serum creatinine above 1.5 times the ULN or;~* Absolute neutrophils counts below 1.5 x 109/L or;~* Platelet count below 100 x 109/L or;~* Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);~* Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;~* Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGM-101 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).